Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor

Cancer

Volumn 86, Issue 10, 1999, Pages 2053-2058

  Cooper, Lucienne S ^a   Gillett, Cheryl E ^a   Patel, Neera K ^a   Barnes, Diana M ^a   Fentiman, Ian S ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Breast carcinoma; Estrogen receptors; Menstrual cycle; Progesterone receptors; Prognosis; Timing of surgery

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER SURVIVAL; FEMALE; FOLLICULAR PHASE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; METASTASIS; PREMENOPAUSE; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MENSTRUAL CYCLE; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0033571533     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991115)86:10<2053::AID-CNCR24>3.0.CO;2-H     Document Type: Article

References (22)

1. Fentiman IS, Gregory WM, Richards MA. Effect of menstrual cycle phase on surgical treatment of breast cancer. Lancet 1994;344:402.
2. Veronesi U, Luini A, Mariani L, Del Vecchio M, Alvez D, Andreoli C, et al. Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994;343:1544-6.
3. Goldhirsch A, Gelber RD, Castiglione M, O'Neill A, Thürlimann B, Rudenstam C-M, et al. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol 1997;8:751-6.
4. Hrushesky WJM, Bluming AZ, Gruber SA, Southern RB. Menstrual influence on surgical cure of breast cancer. Lancet 1989;i:949-53.
5. Powles TJ, Jones AL, Ashley S, Tidy A. Menstrual effect on surgical cure of breast cancer. Lancet 1989;ii:1343-4.
6. Goldhirsch A, Gelber RD, Forbes J, Price K, Castiglione M, Rudenstam C-M, et al. Timing breast cancer surgery. Lancet 1991;338:692.
7. Badwe RA, Gregory WM, Chaudary MA, Richards MA, Bentley AE, Rubens RD, et al. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 1991;337:1261-4.
8. Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. Br J Cancer 1996;73:1552-5.
9. Badwe RA, Bettelheim R, Millis RR, Gregory WM, Richards MA, Fentiman IS. Cyclical tumor variations in premenopausal women with early breast cancer. Eur J Cancer 1995; 31A:2181-4.
10. Cooper LS, Gillett CE, Smith P, Fentiman IS, Barnes DM. Cell proliferation measured by MIB1 and timing of surgery in breast cancer. Br J Cancer 1998;77:1502-7.
11. Van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, et al. Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC Trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer. Eur J Cancer 1992;28A: 801-5.
12. World Health Organization. International histologic diagnosis of tumors. In: Histologic typing of breast tumors. Geneva: World Health Organization, 1981:.
13. Elston CW, Ellis IO. Pathologic prognostic factors in breast cancer. Histopathology 1991;19:403-10.
14. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of estrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996;74:1445-51.
15. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of clinical trials requiring prolonged observation of each patient II: analysis and examples. Br J Cancer 1977;35:1-39.
16. Badwe RA, Richards MA, Fentiman IS, Gregory W, Saad Z, Chaudary MA, et al. Surgical procedures, menstrual cycle phase, and prognosis in operable breast cancer. Lancet 1991;338:815-6.
17. Millis RR. The relationship between pathology of breast cancer and hormone sensitivity. Rev Endocrinol Rel Cancer 1987;20(Suppl):13-8.
18. Skinner LG, Barnes DM, Ribeiro GG. The clinical value of multiple steroid receptor assays in breast cancer management. Cancer 1980;46:2939-45.
19. Söderqvist G, Von Schoultz B, Tani E, Skoog L. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol 1993;168:874-9.
20. Rochefort H. Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer 1992;28A:1780-3.
21. Schweike D, Hin A, Neufeld G, Gitay-Goren H, Keshet E. Patterns of expression of vascular endothelial growth hormone (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 1991;91:2235-43.
22. Heer K, Kumar H, Speirs V, Greenman J, Drew PJ, Fox JN, et al. Vascular endothelial growth factor in premenopausal women - indicator of the best time for breast cancer surgery. Br J Cancer 1998;78:1203-7.